英科医疗(300677) - 2022 Q1 - 季度财报

Financial Performance - Revenue for Q1 2022 was CNY 2,287,865,174, a decrease of 66.03% compared to CNY 6,734,661,831 in the same period last year[3] - Net profit attributable to shareholders was CNY 83,493,070, down 97.77% from CNY 3,735,722,692 year-on-year[3] - Basic earnings per share decreased to CNY 0.15, a decline of 97.93% from CNY 7.24 in the previous year[3] - Total operating revenue for the current period is 2,287,865,174.00, a decrease of approximately 66.0% compared to the previous period's 6,734,661,831.00[30] - The net profit for the current period is 79,471,291.00, compared to 3,734,237,292.00 in the previous period, indicating a significant decrease[33] - The total profit for the current period is 104,876,218.00, down from 4,422,209,795.00 in the previous period[33] - The operating profit for the current period is 108,517,738.00, compared to 4,424,020,628.00 in the previous period[33] - The total comprehensive income for the current period is 76,357,401.00, compared to 3,739,918,415.00 in the previous period[36] - The company reported a decrease in sales revenue from 5,396,786,425.00 in the previous period to 1,977,957,759.00 in the current period[37] Cash Flow and Assets - Net cash flow from operating activities was CNY 416,703,728, down 86.45% from CNY 3,075,354,570 in the same period last year[3] - The company's cash and cash equivalents at the end of March 2022 amount to ¥4,819,885,228, down from ¥5,002,855,287 at the beginning of the year[20] - The cash flow from operating activities for the current period is 416,703,728.00, a decrease from 3,075,354,570.00 in the previous period[40] - The cash and cash equivalents at the end of the period are 4,796,143,801.00, down from 6,934,091,947.00 in the previous period[43] - The net cash flow from investing activities is -878,548,703.00, compared to -1,135,811,036.00 in the previous period[40] - The net cash flow from financing activities is 304,588,408.00, an increase from 52,681,053.00 in the previous period[40] - Total assets at the end of Q1 2022 were CNY 20,557,983,278, a slight decrease of 0.32% from CNY 20,624,644,774 at the end of the previous year[3] - The company's total assets amount to 20,557,983,278.00, slightly down from 20,624,644,774.00 in the previous period[29] - The company's cash and cash equivalents have decreased, with total current assets at 10,437,677,802.00 compared to 10,762,722,389.00 previously, a decline of about 3.0%[29] Liabilities and Shareholder Information - The company reported a significant increase in short-term borrowings, which rose by 519.04% to CNY 312,517,672[6] - The company’s long-term borrowings have increased to 243,714,318.00 from 198,500,000.00, reflecting a growth of approximately 22.8%[26] - Total liabilities are reported at 4,352,063,434.00, a decrease from 4,501,196,482.00 in the previous period[29] - Total number of common shareholders at the end of the reporting period is 97,156, with the largest shareholder, Liu Fangyi, holding 35.06% of shares, equating to 192,684,673 shares[10] - Liu Fangyi holds 48,171,168 unrestricted shares, while Hong Kong Central Clearing Limited holds 11,722,848 unrestricted shares[14] - The total equity attributable to shareholders of the parent company is 15,957,689,079.00, up from 15,871,195,748.00, indicating a growth of about 0.5%[29] Research and Development - Research and development expenses decreased by 32.44% to CNY 69,568,207 compared to CNY 102,972,246 in the same period last year[6] - Research and development expenses for the current period amount to 69,568,207.00, a decrease of approximately 32.4% from 102,972,246.00 in the previous period[30] Other Income and Investments - Other income increased by 389.18% to CNY 18,853,836, primarily due to government subsidies received[9] - The company has a significant focus on expanding its investment channels and diversifying investment risks[19] - The company invested ¥30 million in Wuxi Shangxianhu Boshang Investment Partnership to expand investment channels[19] - The company is actively pursuing overseas strategic mergers and acquisitions through investments in partnerships[19] - A total of 433,930 restricted shares were repurchased and canceled by the company in February 2022[19] - The subsidiary Anhui Kaize New Materials Co., Ltd. has entered trial production for a project with an annual capacity of 500,000 tons of carboxylated nitrile latex[19]